DRAK2 has been recently suggested to be involved in the development of NAFLD by inhibiting the phosphorylation of serine-arginine-containing splicing factor 6 (SRSF6) by SRSF protein kinase 1 (SRPK1) through binding to SRSF6 (Li et al., 2021). This evidence concerns the gene STK17B and metabolic dysfunction-associated steatotic liver disease.